Cabenuva is a 2-drug co-packaged product of cabotegravir, a HIV-1 integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI).
Patient Engagement in Care with Cabenuva
Viremic Events and Blips in Patients Receiving Cabenuva
Effectiveness of CABENUVA in the Real World
Use of Cabenuva in People with Adherence Challenges
Use of Cabenuva in People with a High Body Mass Index
Call 1-888-226-8434
Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)
Report an Adverse Event
To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at https://gsk.public.reportum.com or 1-877-844-8872, or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.
This site is intended for US Healthcare Professionals Only. It may include information about products or uses that have not been approved by the US Food and Drug Administration.
Trademarks are owned by or licensed to the ViiV Healthcare group of companies.
©2025 ViiV Healthcare group of companies or its licensor. Produced in USA. February 2025